Endocannabinoid system and stress and anxiety responses

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 2 SPEC. ISS., 2005, Pages 331-342

  Viveros, M P ^a   Marco, Eva M ^a   File, Sandra E ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adrenocortical activity; Anxiety; Bimodal effects; Cannabinoids; Cholecystokinin; GABA A; Opioid and Serotonergic systems

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ANANDAMIDE; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BROMAZEPAM; BUSPIRONE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CHOLECYSTOKININ; COCAINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; FLUMAZENIL; HU 219; HU 252; HU 261; HYDROLASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NABILONE; OPIATE; RIMONABANT; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; URB 532; URB 587;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADRENAL CORTEX; AMYGDALOID NUCLEUS; ANOREXIA; ANXIETY DISORDER; BRAIN CORTEX; BRAIN INJURY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHRONIC PAIN; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG EFFECT; DRUG METABOLISM; DRUG TARGETING; EMOTIONAL STRESS; ENVIRONMENT; HIPPOCAMPUS; HUMAN; MOOD DISORDER; MOUSE MUTANT; MULTIPLE SCLEROSIS; NAUSEA; NERVE DEGENERATION; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DENSITY; SEROTONINERGIC SYSTEM; SPASTICITY; TRANQUILIZING ACTIVITY; VOMITING;

ANIMALIA;

EID: 20444379218     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.01.029     Document Type: Conference Paper

References (128)

1. C. Arévalo, R. De Miguel, and R. Hernández-Tristán Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters Pharmacol Biochem Behav 70 2001 123 131
2. J.C. Arnold, A.N. Topple, P.E. Mallet, G.E. Hunt, and I.S. McGregor The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain Brain Res 921 2001 240 255 [Erratum in: Brain Res 2002;934:168]
3. M. Arnone, J. Maruani, F. Chaperon, M.H. Thiebot, M. Poncelet, and P. Soubrie Selective inhibition of sucrose and ethanol intake by rimonabant, an antagonist of central cannabinoid (CB1) receptors Psychopharmacology 132 1997 104 106
4. C.H. Ashton Pharmacology and effects of cannabis: a brief review Br J Psychiatry 178 2001 101 106
5. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 1999 1083 1152
6. M.C. Beinfeld, and K. Connolly Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids Neurosci Lett 301 2001 69 71
7. F. Berrendero, and R. Maldonado Involvement of the opioid system in the anxiolytic-like effects induced by Delta (9)-tetrahydrocannabinol Psychopharmacology 163 2002 111 117
8. E. Borcel, L. Pérez-Alvarez, M.L. de Ceballos, B.G. Ramirez, E.M. Marco, and B. Fernández Functional responses to the cannabinoid agonist WIN 55,212-2 in neonatal rats of both genders: influence of weaning Pharmacol Biochem Behav 78 2004 593 602
9. A. Boys, S. Lenton, and K. Norcross Polydrug use at raves by a Western Australian sample Drug Alcohol Rev 16 1997 227 234
10. D. Braida, M. Pozzi, R. Cavallini, and M. Sala Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system Neuroscience 104 2001 923 926
11. C.S. Breivogel, G. Griffin, V. Di Marzo, and B.R. Martin Evidence for a new G protein-coupled cannabinoid receptor in mouse brain Mol Pharmacol 60 2001 155 163
12. A. Castañé, E. Valjent, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence Neuropharmacology 43 2002 857 867
13. F. Chaperon, and M.H. Thiebot Behavioral effects of cannabinoid agents in animals Crit Rev Neurobiol 13 1999 243 281
14. S. Cheeta, P.J. Kenny, and S.E. File Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety Prog Neuropsychopharmacol Biol Psychiatry 24 2000 1053 1067
15. S. Cheeta, E.E. Irvine, S. Tucci, J. Sandhu, and S.E. File In adolescence, female rats are more sensitive to the anxiolytic effect of nicotine than are male rats Neuropsychopharmacology 25 2001 601 607
16. 1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 2002 451 463
17. D.E. Comings, D. Muhleman, R. Gade, P. Johnson, R. Verde, and G. Saucier Cannabinoid receptor gene (CNR1): association with i.v. drug use Mol Psychiatry 2 1997 161 168
18. J.A. Crippa, A.W. Zuardi, G.E. Garrido, L. Wichert-Ana, R. Guarnieri, and L. Ferrari Effects of cannabidiol (CBD) on regional cerebral blood flow Neuropsychopharmacology 29 2004 417 426
19. J.L. Croxford Therapeutic potential of cannabinoids in CNS disease CNS Drugs 17 3 2003 179 202
20. P.N. Dannon, K. Lowengrub, R. Amiaz, L. Grunhaus, and M. Kotler Comorbid cannabis use and panic disorder: short term and long term follow-up study Hum Psychopharmacol 19 2004 97 101
21. E.R. De Kloet Hormones, brain and stress Endocr Regul 37 2003 51 68
22. S.E. De Rosset, and S.G. Holtzman Effects of opiate antagonists and putative kappa agonists on unpunished and punished operant behavior in the rat Psychopharmacology 86 1985 386 391
23. A.C. DeVries, and A. Pert Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor Psychopharmacology 137 1998 333 340
24. S. Di, R. Malcher-Lopes, K.C. Halmos, and J.G. Tasker Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism J Neurosci 23 2003 4850 4857
25. V. Di Marzo, C.S. Breivogel, Q. Tao, D.T. Bridgen, R.K. Razdan, and A.M. Zimmer Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain J Neurochem 75 2000 2434 2444
26. S.E. File Behavioural detection of anxiolytic action J.M. Elliot D.J. Heal C.A. Marsden Experimental approaches to anxiety and depression 1992 Wiley New York 25 44
27. S.E. File, P.S. Mabbutt, and P.K. Hitchcott Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze Psychopharmacology 102 1990 98 101
28. S.E. File, L.E. Gonzalez, and N. Andrews Comparative study of pre- and post-synaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests J Neurosci 16 1996 4810 4815
29. S.E. File, E. Fluck, and A. Leahy Nicotine has calming effects on stress-induced mood changes in females, but enhances aggressive mood in males Int J Neuropsychopharmacol 4 2001 371 376
30. S.E. File, S. Cheeta, E.E. Irvine, S. Tucci, and M. Akthar Conditioned anxiety to nicotine Psychopharmacology 164 2002 309 317
31. S.E. File, A.K. Dinnis, J.E. Heard, and E.E Irvine Mood differences between male and female light smokers and nonsmokers Pharmacol Biochem Behav 72 2002 681 689
32. E. Fride, and E. Shohami The endocannabinoid system: function in survival of the embryo, the newborn and the neuron Neuroreport 13 2002 1833 1841
33. R.W. Fuller The involvement of serotonin in regulation of pituitary-adrenocortical function Front Neuroendocrinol 13 1992 250 270
34. S. Gaetani, V. Cuomo, and D. Piomelli Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 9 2003 474 478
35. I. Galve-Roperh, C. Sanchez, M.L. Cortes, T. Gomez del Pulgar, M. Izquierdo, and M. Guzman Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation Nat Med 6 2000 313 319
36. R.F. Genn, S. Tucci, E. Marco, M.P. Viveros, and S.E. File Anxiolytic and anxiogenic effects of the cannabinoid agonist CP 55,940 in animal tests of anxiety J Psychopharmacol 17 2003 A27
37. R.F. Genn, S. Tucci, E.M. Marco, M.P. Viveros, and S.E. File Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test Pharmacol Biochem Behav 77 2004 567 573
38. R.F. Genn, S. Tucci, S. Parikh, and S.E. File Effects of nicotine and a cannabinoid receptor agonist on negative contrast: distinction between anxiety and disappointment? Psychopharmacology 177 2004 93 99
39. S. Ghozland, H.W. Matthes, F. Simonin, D. Filliol, B.L. Kieffer, and R. Maldonado Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors J Neurosci 22 2002 1146 1154
40. D. Giuliani, F. Ferrari, and A. Ottani The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress Pharmacol Res 41 2000 47 53
41. M. Glass, M. Dragunow, and R. Faull Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain Neuroscience 77 1997 299 331
42. N.E. Goeders A neuroendocrine role in cocaine reinforcement Psychoneuroendocrinology 22 1997 237 259
43. N.E. Goeders The HPA axis and cocaine reinforcement Psychoneuroendocrinology 27 2002 13 33
44. 1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze Brain Res 732 1996 145 153
45. L.E. González, A.M. Ouagazzal, and S.E. File Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphe reveals differential GABAergic control in two animal tests of anxiety Eur J Neurosci 10 1998 3673 3680
46. S. González, M.G. Cascio, J. Fernandez-Ruiz, F. Fezza, V. Di Marzo, and J.A. Ramos Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine Brain Res 954 2002 73 81
47. G. Griebel 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research Pharmacol Ther 65 1995 319 395
48. G. Griebel, R.J. Rodgers, G. Perrault, and D.J. Sanger Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test Pharmacol Biochem Behav 57 1997 817 827
49. G. Griebel, R.J. Rodgers, G. Perrault, and D.J. Sanger The effects of compounds varying in selectivity as 5-HT1A receptor antagonists in three rat models of anxiety Neuropharmacology 39 2000 1848 1857
50. F.S. Guimarães, T.M. Chiaretti, F.G. Graeff, and A.W. Zuardi Antianxiety effect of cannabidiol in the elevated plus-maze Psychopharmacology 100 1990 558 559
51. F.S. Guimarães, J.C. de Aguiar, R. Mechoulam, and A. Breuer Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze Gen Pharmacol 25 1994 161 164
52. N. Hàjos, and T.F. Freund Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition Chem Phys Lipids 121 2002 73 82
53. N. Hàjos, C. Ledent, and T.F. Freund Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus Neuroscience 106 2001 1 4
54. W. Hall, and N. Solowij Adverse effects of cannabis Lancet 352 1998 1611 1616
55. W. Hall, N. Solowij, and J. Lemon The health and psychological consequences of cannabis use Monograph Series-National Drug Strategy vol. 25 1994 Australian Government Publishing Service Canberra
56. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur J Neurosci 16 2002 1395 1398
57. J. Haller, B. Varga, C. Ledent, I. Barna, and T.F. Freund Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice Eur J Neurosci 19 2004 1906 1912
58. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, and B.R. de Costa Cannabinoid receptor localization in brain Proc Natl Acad Sci U S A 87 1990 1932 1936
59. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J Neurosci 11 1991 563 583
60. 1 receptor agonist HU-210 following chronic stress Eur J Pharmacol 499 2004 291 295
61. LE. Hollister Health aspects of cannabis Pharmacol Rev 38 1986 1 20
62. A. Holmes Targeted gene mutation approaches to the study of anxiety-like behavior in mice Neurosci Behav Rev 25 2001 261 273
63. 9 THC and anandamide Brain Res 857 2000 337 342
64. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, and W.A. Devane International Union of Pharmacology. XXVII: classification of cannabinoid receptors Pharmacol Rev 54 2002 161 202
65. B.L. Hungund, and B.S. Basavarajappa Are anandamide and cannabinoid receptors involved in ethanol tolerance? A review of the evidence Alcohol Alcohol 35 2000 126 133
66. Z. Jarai, J.A. Wagner, K. Varga, K.D. Lake, D.R. Compton, and B.R. Martin Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors Proc Natl Acad Sci U S A 96 1999 14136 14141
67. S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, and A. Tontini Modulation of anxiety through blockade of anandamide hydrolysis Nat Med 9 2003 76 81
68. I. Katona, B. Sperlagh, A. Sik, A. Kafalvi, E.S. Vizi, and K. Mackie Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons J Neurosci 19 1999 4544 4558
69. I. Katona, E.A. Rancz, L. Acsady, C. Ledent, K. Mackie, and N. Hajos Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission J Neurosci 21 2001 9506 9518
70. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 1999 283401 283404
71. M. Lepore, S.R. Vorel, J. Lowinson, and E.L. Gardner Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward Life Sci 56 1995 2073 2080
72. M. Maccarrone, O. Valverde, M.L. Barbaccia, A. Castañé, R. Maldonado, and C. Ledent Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour Eur J Neurosci 15 2002 1178 1186
73. D.T. Malone, and D.A. Taylor Involvement of somatodendritic 5-HT1A receptors in Delta (9)-terahydrocannabinol-induced hypothermia in the rat Pharmacol Biochem Behav 69 2001 595 601
74. 9-tetrahydrocannabinol in rats Brain Res 839 1999 173 179
75. J. Manzanares, J. Corchero, J. Romero, J.J. Fernández-Ruiz, J.A. Ramos, and JA Fuentes Pharmacological and biochemical interactions between opioids and cannabinoids Trends Pharmacol Sci 20 1999 287 294
76. E.M. Marco, L. Perez-Alvarez, E. Borcel, M. Rubio, C. Guaza, and E. Ambrosio Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats Behav Pharmacol 15 2004 21 27
77. E.M. Marco, L. Perez-Alvarez, E. Borcel, M. Rubio, C. Guaza, and E. Ambrosio Involvement of the 5-HT1A receptors in behavioural and endocrine effects of CP 55,940 in rats 5th Morzine Meeting, France 2004
78. S. Marín, E. Marco, M. Biscaia, B. Fernandez, M. Rubio, and C. Guaza Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats Pharmacol Biochem Behav 74 2003 649 656
79. G. Marsicano, and B. Lutz Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain Eur J Neurosci 11 1999 4213 4225
80. G. Marsicano, C.T. Wotjak, S.C. Azad, T. Bisogno, G. Rammes, and M.G. Cascio The endogenous cannabinoid system controls extinction of aversive memories Nature 418 2002 530 534
81. M. Martín, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Involvement of CB1 cannabinoid receptors in emotional behaviour Psychopharmacology 159 2002 379 387
82. J.L. Martín-Calderón, R.M. Muñoz, M.A. Villanua, I. del Arco, J.L. Moreno, and F.R. de Fonseca Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats Eur J Pharmacol 344 1998 77 86
83. M.S. Mascia, M.C. Obinu, C. Ledent, M. Parmentier, G.A. Bohme, and A. Imperato Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice Eur J Pharmacol 383 1999 R1 R2
84. P. Massi, A. Vaccani, S. Ceruti, A. Colombo, M.P. Abbracchio, and D. Parolaro Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines J Pharmacol Exp Ther 308 2004 838 845
85. I.S. McGregor, F.N. Dastur, R.A. McLellan, and R.E. Brown Cannabinoid modulation of rat pup ultrasonic vocalizations Eur J Pharmacol 313 1996 43 49
86. I.S. McGregor, C.N. Issakidis, and G. Prior Aversive effects of the synthetic cannabinoid CP 55,940 in rats Pharmacol Biochem Behav 53 1996 657 664
87. M.J. Millan The neurobiology and control of anxious states Prog Neurobiol 70 2003 83 244
88. K.C. Morley, K.M. Li, G.E. Hunt, P.E. Mallet, and I.S. McGregor Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats Neuropharmacology 46 2004 954 965
89. M.B. Muller, S. Zimmermann, I. Sillaber, T.P. Hagemeyer, J.M. Deussing, and P. Timpl Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress Nat Neurosci 6 2003 1100 1107
90. M. Navarro, E. Hernández, R.M. Muñoz, I. Del Arco, M.A. Villanúa, and M.R.A. Carrera Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat Neuroreport 8 1997 491 496
91. M.J. Nobre, N. Ribeiro dos Santos, M.S. Aguiar, and M.L. Brandao Blockade of μ- and activation of κ-opioid receptors in the dorsal periaqueductal gray matter produce defensive behavior in rats tested in the elevated plus-maze Eur J Pharmacol 404 2000 145 151
92. E.S. Onaivi, M.R. Green, and B.R. Martin Pharmacological characterization of cannabinoids in the elevated plus maze J Pharmacol Exp Ther 253 1990 1002 1009
93. S. Patel, C.T. Roelke, D.J. Rademacher, W.E. Cullinan, and C.J. Hillard Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis Endocrinology 145 2004 5431 5438
94. G.C. Patton, C. Coffey, J.B. Carlin, L. Degenhardt, M. Lynskey, and W. Hall Cannabis use and mental health in young people: cohort study BMJ 325 2002 1195 1198
95. M. Pistis, S. Perra, G. Pillolla, M. Melis, G.L. Gessa, and A.L. Muntoni Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions Neuropharmacology 46 2004 115 125
96. A.C. Porter, and Ch.C. Felder The endocannabinoid nervous system: unique opportunities for therapeutic intervention Pharmacol Ther 90 2001 45 60
97. G. Pugh Jr., D.J. Mason Jr., V. Combs, and S.P. Welch Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP 55,940 in the spinal cord J Pharmacol Exp Ther 281 1997 730 737
98. P. Robson Therapeutic aspects of cannabis and cannabinoids Br J Psychiatry 178 2001 107 115
99. R.J. Rodgers, J. Haller, J. Halasz, and E. Mikics 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze Eur J Neurosci 17 2003 1279 1286
100. F. Rodríguez de Fonseca, P. Rubio, F. Menzaghi, E. Merlo-Pich, J. Rivier, and G.F. Koob Corticotropin-releasing factor (CRF) antagonist [d-Phe12, Nle21,38, C alpha MeLeu37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats J Pharmacol Exp Ther 276 1996 56 64
101. E.M. Romero, B. Fernández, O. Sagredo, N. Gómez, L. Urigüen, and C. Guaza Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats Dev Brain Res 136 2002 85 92
102. S. Rotzinger, and F.J. Vaccarino Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models J Psychiatry Neurosci 28 2003 171 181
103. M. Sakaue, Y. Ago, C. Sowa, Y. Koyama, A. Baba, and T. Matsuda The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze Eur J Pharmacol 458 2003 141 144
104. J.J. Sandford, S.V. Argyropoulos, and D.J. Nutt The psychobiology of anxiolytic drugs: Part 1. basic neurobiology Pharmacol Ther 88 2000 197 212
105. A.B. Sante, M.J. Nobre, and M.L. Brandao Place aversion induced by blockade of mu or activation of kappa opioid receptors in the dorsal periaqueductal gray matter Behav Pharmacol 11 2000 583 589
106. R. Siliquini, F. Faggiano, S. Geninatti, E. Versino, B. Mitola, and R. Ippolito Patterns of drug use among young men in Piedmont (Italy) Drug Alcohol Depend 64 2001 329 335
107. E. Sulcova, R. Mechoulam, and E. Fride Biphasic effects of anandamide Pharmacol Biochem Behav 59 1998 347 353
108. L. Topp, J. Hando, P. Dillon, A. Roche, and N. Solowij Ecstasy use in Australia: patterns of use and associated harm Drug Alcohol Depend 55 1999 105 115
109. M. Tournier, F. Sorbara, C. Gindre, J.D. Swendsen, and H. Verdoux Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population Psychiatry Res 118 2003 1 8
110. K. Tsou, K. Mackie, M.C. Sanudo-Pena, and J.M. Walker Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation Neuroscience 93 1999 969 975
111. S. Tucci, S. Cheeta, R.F. Genn, P. Seth, and S.E. File Anxiety conditioned to nicotine in the elevated plus-maze is time dependent Behav Pharmacol 13 2002 615 620
112. S. Tucci, S. Cheeta, P. Seth, and S.E. File Corticotropin releasing factor antagonist α-helical CRF9-41, reverses nicotine-induced conditioned, but not unconditioned, anxiety Psychopharmacology 167 2003 251 256
113. E.T. Tzavara, M. Wade, and G.G. Nomikos Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action J Neurosci 23 2003 9374 9384
114. L. Urigüen, S. Perez-Rial, C. Ledent, T. Palomo, and J. Manzanares Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB(1) receptors Neuropharmacology 46 2004 966 973
115. E. Valjent, and R. Maldonado A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice Psychopharmacology 147 2000 436 438
116. E. Valjent, J.M. Mitchell, M.J. Besson, J. Caboche, and R. Maldonado Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine Br J Pharmacol 135 2002 564 578
117. O. Valverde, C. Ledent, F. Beslot, M. Parmentier, and B.P. Roques Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors Eur J Neurosci 12 2000 533 539
118. 9-Tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect Eur J Neurosci 13 2001 1816 1824
119. A. Vicentic, Q. Li, G. Battaglia, and L.D. Van de Kar WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion Eur J Pharmacol 346 1998 261 266
120. J. Weidenfeld, S. Feldman, and R. Mechoulam Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat Neuroendocrinology 59 1994 110 112
121. S.P. Welch, and M. Eads Synergistic interactions of endogenous opioids and cannabinoid systems Brain Res 848 1999 183 190
122. T. Wenger, K.A. Jamali, C. Juaneda, J. Leonardelli, and G. Tramu Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus Biochem Biophys Res Commun 237 1997 724 728
123. E.M. Williamson, and F.J. Evans Cannabinoids in clinical practice Drugs 60 2000 1303 1314
124. A.R. Winstock, P. Griffiths, and D. Stewart Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK Drug Alcohol Depend 64 2001 9 17
125. T. Yamamoto, and K. Takada Role of cannabinoid receptors in the brain as it relates to drug reward Jpn J Pharmacol 84 2000 229 236
126. A. Zimmer, A.M. Zimmer, A.G. Hohmann, M. Herkenham, and TI. Bonner Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc Natl Acad Sci U S A 96 1999 5780 5785
127. A. Zimmer, E. Valjent, M. König, A.M. Zimmer, P. Robledo, and H. Hahn Absence of Δ-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice J Neurosci 21 2001 9499 9505
128. A.W. Zuardi, I. Shirakawa, E. Finkelfarb, and I.G. Karniol Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects Psychopharmacology 76 1982 245 250